Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David R Cassatt

Showing results (1-10 of 26) with videos related to

Pageof 3
Sort By:
Radiation Research|October 29, 2021
A Trans-Agency Workshop on the Pathophysiology of Radiation-Induced Lung InjuryMerriline M Satyamitra, David R Cassatt, Libero Marzella
Radiation Research|September 13, 2023
Immune Dysfunction from Radiation ExposureDavid R Cassatt, Thomas A Winters, Mercy PrabhuDas
Radiation Research|February 26, 2024
Product Development within the National Institutes of Health Radiation and Nuclear Countermeasures ProgramDavid R Cassatt, Andrea L DiCarlo, Olivia Molinar-Inglis
Seminars in Oncology|January 17, 2004
Effects of dose and schedule on the efficacy of ethyol: preclinical studiesDavid R Cassatt, Christine A Fazenbaker, Gizachew Kifle, et al.
International Journal of Radiation Oncology, Biology, Physics|October 8, 2003
Subcutaneous administration of amifostine (ethyol) is equivalent to intravenous administration in a rat mucositis modelDavid R Cassatt, Christine A Fazenbaker, Gizachew Kifle, et al.
Seminars in Oncology|February 11, 2003
Preclinical studies on the radioprotective efficacy and pharmacokinetics of subcutaneously administered amifostineDavid R Cassatt, Christine A Fazenbaker, Gizachew Kifle, et al.
Radiation Research|July 8, 2021
Meeting Report: A Poly-Pharmacy Approach to Mitigate Acute Radiation SyndromeLanyn P Taliaferro, David R Cassatt, Zulmarie Perez Horta, et al.
Seminars in Radiation Oncology|March 28, 2002
Preclinical modeling of improved amifostine (Ethyol) use in radiation therapyDavid R Cassatt, Christine A Fazenbaker, Christine M Bachy, et al.
Oncology|November 24, 2004
Tissue levels of WR-1065, the active metabolite of amifostine (Ethyol), are equivalent following intravenous or subcutaneous administration in cynomolgus monkeysChristine M Bachy, Christine A Fazenbaker, Gizachew Kifle, et al.
International Journal of Radiation Oncology, Biology, Physics|February 15, 2005
Amifostine (ETHYOL) protects rats from mucositis resulting from fractionated or hyperfractionated radiation exposureDavid R Cassatt, Christine A Fazenbaker, Christine M Bachy, et al.
Pageof 3

Showing results (1-10 of 26) with videos related to

Sort By:
Pageof 3
Radiation Research|October 29, 2021
A Trans-Agency Workshop on the Pathophysiology of Radiation-Induced Lung InjuryMerriline M Satyamitra, David R Cassatt, Libero Marzella
Radiation Research|September 13, 2023
Immune Dysfunction from Radiation ExposureDavid R Cassatt, Thomas A Winters, Mercy PrabhuDas
Radiation Research|February 26, 2024
Product Development within the National Institutes of Health Radiation and Nuclear Countermeasures ProgramDavid R Cassatt, Andrea L DiCarlo, Olivia Molinar-Inglis
Seminars in Oncology|January 17, 2004
Effects of dose and schedule on the efficacy of ethyol: preclinical studiesDavid R Cassatt, Christine A Fazenbaker, Gizachew Kifle, et al.
International Journal of Radiation Oncology, Biology, Physics|October 8, 2003
Subcutaneous administration of amifostine (ethyol) is equivalent to intravenous administration in a rat mucositis modelDavid R Cassatt, Christine A Fazenbaker, Gizachew Kifle, et al.
Seminars in Oncology|February 11, 2003
Preclinical studies on the radioprotective efficacy and pharmacokinetics of subcutaneously administered amifostineDavid R Cassatt, Christine A Fazenbaker, Gizachew Kifle, et al.
Radiation Research|July 8, 2021
Meeting Report: A Poly-Pharmacy Approach to Mitigate Acute Radiation SyndromeLanyn P Taliaferro, David R Cassatt, Zulmarie Perez Horta, et al.
Seminars in Radiation Oncology|March 28, 2002
Preclinical modeling of improved amifostine (Ethyol) use in radiation therapyDavid R Cassatt, Christine A Fazenbaker, Christine M Bachy, et al.
Oncology|November 24, 2004
Tissue levels of WR-1065, the active metabolite of amifostine (Ethyol), are equivalent following intravenous or subcutaneous administration in cynomolgus monkeysChristine M Bachy, Christine A Fazenbaker, Gizachew Kifle, et al.
International Journal of Radiation Oncology, Biology, Physics|February 15, 2005
Amifostine (ETHYOL) protects rats from mucositis resulting from fractionated or hyperfractionated radiation exposureDavid R Cassatt, Christine A Fazenbaker, Christine M Bachy, et al.
Pageof 3